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To our knowledge, no comprehensive, interdisci-plinary initiatives have been taken to examine the
role of genetic variants on patient-reported quality-
of-life outcomes. The overall objective of this paper
is to describe the establishment of an international
and interdisciplinary consortium, the GENEQOL
Consortium, which intends to investigate the
genetic disposition of patient-reported quality-of-life
outcomes. We have identified five primary patient-
reported quality-of-life outcomes as initial targets:
negative psychological affect, positive psychological
affect, self-rated physical health, pain, and fatigue.
The first tangible objective of the GENEQOL
Consortium is to develop a list of potential biological
pathways, genes and genetic variants involved in
these quality-of-life outcomes, by reviewing current
genetic knowledge. The second objective is to
design a research agenda to investigate and validate
those genes and genetic variants of patient-reported
quality-of-life outcomes, by creating large datasets.
During its first meeting, the Consortium has dis-
cussed draft summary documents addressing these
questions for each patient-reported quality-of-life
outcome. A summary of the primary pathways and
robust findings of the genetic variants involved is
presented here. The research agenda outlines possi-
ble research objectives and approaches to examine
these and new quality-of-life domains. Intriguing
questions arising from this endeavor are discussed.
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Insight into the genetic versus environmental com-
ponents of patient-reported quality-of-life outcomes
will ultimately allow us to explore new pathways for
improving patient care. If we can identify patients
who are susceptible to poor quality of life, we will be
able to better target specific clinical interventions to
enhance their quality of life and treatment outcomes.
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Patient-Reported Quality-of-Life Outcomes
The objective of disease-based quality-of-life research is
to gain insight into the impact of disease and treatment
on patient-reported outcomes and, thus, to enhance
patients’ well-being. Patient-reported quality of life
refers to the physical, functional, and psychosocial con-
sequences of disease and treatment as experienced by
patients themselves. Thus, by definition, it is the subjec-
tive experience reflecting the patients’ point of view.
Much progress has been made in recent years in terms
of finding ways to incorporate the patients’ subjective
experience into medical research. Indeed, validated
patient-reported quality-of-life instruments are now
available and empirical evidence about disease and
treatment outcomes has been collected for most disease
sites and treatment modalities. Perhaps the most
provocative finding in this area of research is that
patient-reported quality of life is often superior to more
objective clinical assessments for predicting patients’
survival (Gotay et al., 2008).
Patient-reported quality of life is not only affected
by disease and treatment. Recent data provided prelimi-
nary evidence that the genetic disposition of patients
may impact their quality of life. Research on twins has
provided ample empirical evidence of a genetic predis-
position for negative emotional states, such as
depression, anxiety, and psychosocial distress. To
provide an example of the latter state, Rijsdijk and col-
leagues (2003) found that the overall heritability of
psychosocial distress as assessed with the General
Health Questionnaire ranged from 20% to 44%.
Additionally, an increasing number of studies showed
substantial heritability of positive emotional states, such
as subjective wellbeing and life satisfaction. Heritability
estimates ranged between 40% and 50%, whereas the
remaining variance was accounted for by environmen-
tal influences unique to an individual. No effects of
environmental influences shared by members of the
same family were found (Bergeman et al., 1991; Harris
et al., 1992b; Lykken & Tellegen, 1996; Newman et al.,
1998; Røysamb et al., 2002, 2003; Stubbe et al., 2005;
Tellegen et al., 1988; Nes et al., 2006).
Genetic influences have also been reported for self-
rated health (Christensen et al., 1999; Harris et al.,
1992a; Kendler et al., 2000; Leinonen et al., 2005;
Romeis et al., 2000; Røysamb et al., 2003;
Silventoinen et al., 2007; Svärdh et al., 1998; Svedberg
et al., 2001, 2005, 2006). Typically, in these studies,
health is assessed with the use of either a short scale or
a single item, such as the question: ‘How would you
rate your health in general?’ (Christensen et al., 1999).
To our knowledge, only one study examined the heri-
tability of patient-reported quality of life as assessed
with the SF-36, the most widely used generic health
status questionnaire, in a non-clinical, community
sample of middle-aged males. This study also indi-
cated genetic effects, albeit of a moderate magnitude
(Romeis et al., 2005). To date, the precise amount of
the variance in self-rated health that is accounted for
by genetic factors is unknown.
Sloan & Zhao (2006) were the first to examine the
direct link between polymorphisms and cancer patients’
quality of life, using a large randomized North Central
Cancer Treatment Group clinical trial. A clinically
meaningful effect size was prespecified that would have
to be observed to indicate a potential relationship.
More than triple the number of relationships between
genetic variables and patient-reported quality-of-life
outcomes were observed than would be expected by
chance alone. They found evidence for relationships
between overall quality of life, symptom distress, and
fatigue with variant genotypes of three enzymes
involved in folate metabolisms, dihydropyrimidine
dehydrogenase (DPYD), methy lenetetra hydrofolate
reductase (MTHFR), and thymidylate synthetase
(TYMS). Recently, Yang et al. (2009) evaluated the role
of glutathione-related genotypes on quality of life in
advanced non-small cell lung cancer patients who par-
ticipated in a clinical trial. Patients carrying the
glutathione peroxidase 1 (GPX1-CC) genotype had a
clinically significant decline in overall quality of life,
physical, functional, and emotional well-being. The
authors suggested that GPX1 might be an inherited
factor in predicting patients’ quality of life.
The findings from the few studies performed so far
are sufficiently compelling to justify further exploration
of the relationships between genetic variants and
patient-reported quality-of-life endpoints. The overall
objective of this article is to describe the establishment
of a Consortium, which purports to translate and plan
clinically relevant research to identify and investigate
potential biological pathways, genes and genetic vari-
ants involved in patient-reported quality of life. Insight
into the genetic versus environmental components will
ultimately allow us to explore new pathways for
improving patient care. If we can identify patients who
are susceptible to poor quality of life, we will be able to
better target specific support, such as psychological
and/or pharmacological treatment.
The GENEQOL Consortium
Overall Objective
To our knowledge, no comprehensive, interdiscipli-
nary initiatives have been taken to examine the role of
genetic variants on patient-reported quality-of-life out-
comes and their relevance to disease. We therefore
established the Mayo Clinic/University of Amsterdam
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International Consortium for Genetics and Quality of
Life Research, the GENEQOL Consortium in short.
The overall objective of this Consortium is to establish
strong collaborative and interdisciplinary relationships
to translate and plan clinically relevant research to iden-
tify and investigate potential genes and genetic variants
involved in quality of life. Given the potentially large
number of genetic and quality-of-life variables that
could be explored, there is a danger for unfocused and
individualistic research efforts. Hence, we purport to
adopt a coordinated, focused and efficient approach to
determine the optimal path of exploration to uncover
relationships between genetic variants and quality-of-
life variables. The specific objectives are: (1) to develop
a list of potential biological pathways, genes and
genetic variants involved in quality of life, by reviewing
current genetic knowledge; and (2) to design a research
agenda to investigate and validate those genes and
genetic variants involved in quality of life of individual
patients, by creating large data sets on pooled sources.
Selecting an Initial Set of Patient-Reported
Quality-of-Life Outcomes
Patient-reported quality of life is a multidimensional
construct incorporating at least three broad domains,
that is, physical, psychological, and social. These broad
domains can be further subdivided. For example, physi-
cal functioning can refer to the ability to perform a
range of activities of daily living, as well as physical
symptoms resulting either from the disease itself or
from treatment. Psychological functioning may range
from severe psychological distress to a positive sense of
wellbeing, but may also encompass cognitive function-
ing. Social functioning may refer to quantitative and
qualitative aspects of social relationships and interac-
tions, and may also refer to societal integration. Beyond
this core set of quality-of-life domains, additional issues
may be relevant for specific groups of patients, depend-
ing on the functional domains affected by the disease or
treatment, such as sexual functioning and body image
in patients undergoing mutilating surgery. Additionally,
there is consensus that patient-reported quality-of-life
assessments also entail an overall judgment of health
and/or quality of life (Cella & Tulsky, 1990; Siegrist &
Junge, 1989).
Given this large number of domains, we selected
five important quality-of-life outcomes, i.e., negative
and positive psychological affects, overall health, and
the two most prevalent symptoms across general and
disease populations. The first Consortium activities
were therefore focused on the genetic disposition of: (1)
negative psychological affect (i.e., depression, anxiety,
symptom distress), (2) positive psychological affect (i.e.,
happiness, life satisfaction, subjective well-being,
overall quality of life), (3) perceived or self-rated physi-
cal health, or functioning, (4) pain, and (5) fatigue.
Gathering the Initial Consortium Members
We invited researchers with a strong background and
experience in at least one of the relevant disciplines,
including cellular and molecular biology, behavioral
genetics, pharmacogenetics, oncology, statistical genet-
ics, genetic epidemiology, nursing, medical psychology,
biological psychology, clinical psychology, psychiatry,
and sociology. Additionally, researchers had expertise
in at least one of the identified five quality-of-life
domains. Collectively, this group has an extensive
track record of peer-reviewed articles in highly ranked
journals and successful grant applications obtained
from a wide range of prestigious granting agencies.
The number of participants was limited to 28 to keep
the size of the group manageable and to facilitate the
opportunity for meaningful and directed discussions.
Procedure
The Consortium participants were combined to form
five interdisciplinary teams related to the five identi-
fied quality-of-life outcomes. Each team had a
designated leader and five to six assigned contributors.
Each team was asked the following questions: (1)
which potential biological pathways have been consid-
ered and/or shown to describe a possible genetic
disposition for the indicated quality-of-life outcome?
(2) Which genes and genetic variants have been con-
sidered and/or shown to have a potential association
with the indicated quality-of-life outcome? (3) What
datasets are available to explore the association of
genes and the indicated quality-of-life outcome? (4)
How would you design a new prospective study to
explore the association of genes and the indicated
quality-of-life outcome? Teams were asked to base
their answers on current knowledge (i.e., scientific lit-
erature, ongoing research). The team leaders, in
consultation with their team members, were asked to
produce a 2-3 page draft response to the questions.
The first Consortium meeting took place at the
Mayo Clinic, Rochester, MN on February 26–28, 2009.
It started with an open registration pre-meeting given
by a number of Consortium members summarizing
research in their respective areas of expertise. Given the
multitude of disciplines involved, this workshop pro-
vided a forum for Consortium members to learn of the
advances in other research areas and thus provided an
introduction to the closed meeting. The open registra-
tion meeting purported also to serve as a networking
opportunity for others outside of the Consortium.
The open meeting was followed by a closed 2-day
meeting, which focused on the genetic disposition of
the five quality-of-life outcomes. The teams presented a
30-minute discussion of their responses to the posed
questions and a 60-minute open discussion of the
issues. At the end of each day, a one-and-half hour slot
was devoted to synthesizing the discussions, providing
conclusions regarding the candidate biological path-
ways, genetic variants and the research agenda for the
presented quality-of-life components. The timing of the
conference schedule thus resulted in each topic, includ-
ing the overall discussion, receiving 120 minutes of the
group’s collective attention. The final slot at the end of
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the second day was devoted to wrapping up the discus-
sions, planning the next steps for the Consortium and
assigning tasks and homework to the participants.
Summary of Findings
As a caveat, we would like to note that the description
of the following areas is not intended to be compre-
hensive and that we cannot and do not claim to pay
credit to the depth and richness of these research fields
in the context of this article. Our aim is to stimulate
the investigation of the genetic disposition of these
quality-of-life domains by highlighting the primary
results in the respective fields.
Biological Pathways and Genetic Variables
Negative Psychological Affect
A substantial amount of research related to negative
psychological affect has been conducted in psychiatric
patients; for example, those with major depressive or
anxiety disorder. The focus here is on ‘normal’, non-
pathological, negative feelings, for example, distress in
response to a negative life event, such as the diagnosis
of a disease. Since there is evidence that negative
affect behaves as a continuous trait, we expect a
similar biological substrate for nonpathological as for
pathological negative affect.
The hypothalamo-pituitary-adrenal (HPA) axis is
considered to be the ‘final common pathway’ for most
depressive symptoms (Bao et al., 2008) and thus may
be important for patient-reported distress. The follow-
ing hypothesis for the pathogenesis of depression was
formulated by Bao et al. (2008): ‘In depressed
patients, stress acting on the HPA system results in a
disproportionately high activity of the HPA system
because of a deficient cortisol feedback effect due to
the presence of glucocorticoid resistance’ (p. 541).
Other candidate genes and pathways that may be
involved in depression may result from an impaired
dopamine system (Dunlop & Nemeroff, 2007).
Decreased levels of serotonin are thought to be of
importance in anxiety disorders (Lesch et al., 2003).
Furthermore, changes in sex hormone levels may play
an important role in the vulnerability to mood disor-
ders. Finally, the suprachiasmatic nucleus is supposed
to be related to circadian and circannual fluctuations
in mood and to sleeping disturbances in depression
(Bao et al., 2008).
The following five genes were significantly associ-
ated to major depressive disorder in meta-analysis of
polymorphisms that had been investigated in at least
three studies (López-León et al., 2008): apolipoprotein
E (APOE), guanine nucleotide-binding protein
(GNB3), methylenetetrahydrofolate reductase
(MTHFR), dopamine transporter (SLC6A3), and sero-
tonin transporter (SLC6A4). There are many other
potentially important genes related to the HPA-axis
(e.g., arginine vasopressin, AVP; oxytocin, OXTR),
the dopamine pathway (e.g., dopamine transporter,
DAT; catechol-o-methyltransferase, COMT; and the
D4-receptor, DRD4), and the serotonin pathway (5-
HTT; and monoamide oxidase, MAO-A). The first
genome-wide association (GWA) study of depression
(Sullivan et al., 2009) suggested evidence for the
involvement of the presynaptic protein piccolo (PCLO)
on chromosome 7.
Of all the identified quality-of-life outcomes, negative
psychological affect is the one most widely studied. Since
depression and anxiety disorders are the foci of other
consortia, we decided not to pursue this domain in the
context of the GENEQOL Consortium, other than for
comparison with related quality-of-life domains.
Positive Psychological Affect
The prefrontal cortex is the candidate brain area for
happiness and positive emotional states that may be
related to taste (Kringelbach et al., 2003), smell (Rolls
et al., 2003a) or other input via the somaotosensory
system (Rolls et al., 2003b). Some electro-encephalo-
graphic (EEG) studies suggest that positive affect states
are associated with increased left cortical power in the
alpha frequency compared to the right hemisphere
(Davidson, 2004; Tomarken et al., 1992). There is evi-
dence that dopamine modulates positive affect states
(Burgdorf & Panksepp; 2006). At the subneocortical
level, a number of peptide systems have been implicated
in positive affective states; for example, neurotensin and
cocaine- and amphetamine-regulated transcript (CART)
(both closely associated with dopamine), neuropeptide
Y, and oxytocin (Burgdorf & Panksep, 2006). Finally,
reduced activity of the neuroendocrine (Steptoe et al.
2005a, 2005b, 2008) and cardiovascular systems
(Burgdorf & Panksep, 2006), as well as increased activ-
ity of the immune system (Burgdorf & Panksep, 2006)
may all be involved in positive affect states. However,
genes or genomic regions of interest for positive affect
have not yet been published. 
Physical Health
Separating the biological pathways involved in self-per-
ceived health from those of other health domains is
particularly challenging, since its genetic influence is
related to the genetic liability of a wide variety of related
physical as well as psychological variables. For example,
related physical phenotypes include metabolic efficiency
(Gottfredson, 2004), disease severity, maximal walking
speed and exercise behavior (de Moor, 2007). Related
psychological attributes were found to encompass, for
example, adaptation to stressful environments
(Gottfredson, 2004), resilience to stressful situations
(Curtis et al., 2003), perceived sense of control (Johnson,
2005a; 2005b), intelligence (Gottfredson, 2004), affec-
tive disorders (Vinberg et al., 2007), and depressive
symptoms (Leinonen et al., 2005).
As a result, the list of potential genetic variables
for perceived or self-rated physical health is particu-
larly long. Since one might assume that physical
performance and health-related fitness are also associ-
ated with self-perceived physical health, the list can
easily be expanded. For example, the in 2005 updated
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list for physical performance and health-related fitness
included 156 autosomal gene entries, five others on
the X chromosome, and 17 mitochondrial genes
(Rankinen et al., 2006).
The epsilon4 allele of the APOE gene has been
investigated for association with health-related out-
comes in the elderly (Blazer et al., 2003; Goldman, et
al., 2004). Whereas Blazer and colleagues (2003) did
not find a significant association of APOE4 allele in
cross-sectional or longitudinal analyses of older
adults, Goldman et al. (2004) found that the APOE4
allele was predictive of self-rated health in Taiwanese
respondents aged 54 years and older.
Stress and strain in both work and home environ-
ments are also related with self-rated health (Orpana
et al., 2007; Staland-Nyman et al., 2008; Holmgren et
al., 2009). The battery of stress response genes, espe-
cially the heat shock protein HSP70 genes —
HSPA1A, HSPA1B and HSPA1L — present in the
MHC-III region on the short arm of chromosome 6
have been related to stress response in studies among
Danish twins (Singh et al., 2004). One of the heat
shock protein genes HSP70-1 was found to be related
to poor self-related health (Singh et al., 2007). To our
knowledge, there are no published GWA studies of
genetic determinants of self-reported physical health.
Pain
There are several pathways with a possible genetic dis-
position for pain. The first pathway plays a role in the
central nervous system (CNS). One of its best character-
ized genes codes for catechol-O-methyltransferase
(COMT). COMT mediates the inactivation of cate-
cholamine neurotransmitters, including dopamine,
adrenaline, and noradrenaline. Reduced COMT activ-
ity appears to result in increased sensitivity for pain and
temporal summation of pain (Zubieta et al., 2003).
Studies targeted at the second, peripheral pain
pathway, focus on genes that are involved in neuro-
transmission. Genes evidenced to be associated with
pain perception and responses to analgesics, include,
monoamino-oxidase A (MAO-A) (Shih, 2004),
dopamine receptor (DRD2, DRD3, and DRD4) (Li et
al., 2000), dopamine transporter (DAT) (Cevoli et al.,
2006), adrenergic receptor (ADRB2) (Diatchenko et
al., 2006), serotonin transporter (SLC6A4) (Herken et
al., 2001), transient receptor potential subfamily A
member 1 (TRPA1) (Kim et al., 2004), and TRP sub-
family V member 1 (TRPV1) (Kim et al., 2006) genes.
The third inflammatory, pathway includes
cytokines that are thought to be mediators between
the CNS and the immune system and brain cytokines
that mediate sickness response (Cleeland et al., 2003).
Candidate genes include ligands for interleukin (IL) 1-
receptor (IL-1RN): IL-1α, IL-1β (Solovieva et al.,
2004), IL-6, IL-8, and tumor necrosis factor-alpha
(TNF-α) (Reyes-Gibby et al., 2007, 2008).
The final pathway is involved in the response to
analgesics and includes absorption, metabolism, distri-
bution, and interaction with targets of analgesics. A
range of genetic variations has been identified that alter
the effectiveness of analgesic drugs (Rollason et al.,
2008). Compelling evidence has been found for genetic
variation in the cytochrome P450 (CYP) isoenzyme
CYP2D6 for codeine analgesic efficacy (Sindrup et al.,
1995). Genetic variation in the COMT (Rakvåg et al.,
2005) and mu opioid receptor (OPRM1) genes
(Klepstad et al., 2004) is related to morphine analgesic
efficacy. Evidence for other genes is inconclusive, but
melanocortin-1 receptor (MC1R) (Mogil et al., 2005)
and ABC family member B1 (ABCB1) (Campa et al.,
2007) may be involved. It should be noted that there is
a lack of studies investigating analgesic efficacy for
opioids other than codeine and morphine. A GWA
study among 110 patients with acute post-surgical pain
reported a candidate SNP (rs2562456) associated with
analgesic onset (Kim et al., 2009). Large-scale GWA
studies related to pain have not been published yet.
Fatigue
Cancer-related fatigue can be defined as a ‘persistent,
subjective sense of tiredness related to cancer and
cancer treatment that interferes with usual functioning’
(Mock et al., 2000). Whereas the patho physiological
mechanisms involved in cancer-related fatigue are not
completely understood (Gutstein, 2001), dysregulation
of several systems, both biochemical and physiological,
are likely involved (Ryan et al., 2007). Proposed mech-
anisms of cancer-related fatigue include cytokine
dysregulation, brain serotonin (5-HT) neurotransmit-
ter dysregulation, alterations in adenosine triphosphate
(ATP), muscle metabolism, and vagal afferent activa-
tion, and disruption in circadian rhythm (Ryan et
al., 2007).
Alterations in any part of the circadian system can
result in disruption of arousal and sleep patterns.
Specific suprachiasmatic nuclei (SCN) peptides that
have the ability to regulate activity and sleep patterns,
include epidermal growth factor (EGF), transforming
growth factor-alpha (TGF-α), neuregulin-1 (NRG-1),
prokineticine-2 (PK2), and cardiotrophin-like cytokine
(CLc). All five peptides have been shown to reversibly
inhibit activity and deregulate 24-hour sleep patterns.
Circadian rhythm may also be affected through SCN
downstream signal disruption that occurs in the dorsal
or ventral nuclei or by signals from input from the
brain’s visceral, limbic, and cortical systems.
Several lines of evidence suggest that increased
inflammatory marker levels are related to increased
fatigue (Rich, 2007; Reyes-Gibby et al., 2008;
Collado-Hidalgo et al., 2008; Ahlberg et al., 2004;
Meyers et al., 2005). Gene polymorphisms have been
identified in the regulator (promoter) regions of genes
that encode proinflammatory cytokines. These poly-
morphisms could differentially influence susceptibility
to cancer-related fatigue. Because cancer-related symp-
toms are complex, they are likely to be influenced by
the cumulative effect of several gene polymorphisms
(Reyes-Gibby et al., 2008). Several cytokine genes and
their polymorphisms have been proposed as candidate
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markers for the study of cancer-related fatigue (Reyes-
Gibby et al., 2008). These include IL-1B (Reyes-Gibby
et al., 2008; Collado-Hidalgo et al., 2008); IL-6 (Rich,
2007; Reyes-Gibby et al., 2008; Collado-Hidalgo et
al., 2008; Ahlberg et al., 2004; Meyers et al., 2005);
TNF-α (Bower et al., 2002; Shafqat et al., 2005); IL-8
(Reyes-Gibby et al., 2007, 2008); and IL-2 (Reyes-
Gibby, 2008). To date, there are no published GWA
studies of cancer-related fatigue yet.
Setting Out the Research Agenda
Objectives
We will start studying the genetic underpinning of pos-
itive psychological affect, general physical functioning/
health, pain, and fatigue. We will gradually add new
quality-of-life domains to our research portfolio; for
example, social functioning and other symptoms.
Possible objectives include: (a) to study the biological
pathways that impact the variability in quality-of-life
data; (b) to analyze and compare the association
between genetic and quality-of-life variables extracted
from population-based and patient-based cross-sectional
and longitudinal data sets; (c) to test the genetic differ-
ences in subjects with extreme phenotypes for a single
symptom or symptom clusters; (d) to test differences in
quality of life between subjects grouped according to a
particular genetic makeup (e.g., on the basis of the
number of possible alleles of a particular gene); (e) to
examine the extent to which different quality-of-life
domains share similar genes; (f) to examine the extent to
which different operationalizations of same quality-of-
life domains share similar genes; (g) to examine the effect
of interventions (e.g., cancer therapy, psychosocial inter-
ventions to increase happiness) on the association
between genes/gene expressions on the one hand and
quality-of-life domains (e.g., symptoms, positive affect)
on the other; and (h) to test personalized interventions
using our knowledge of the biological pathways for and
genetic variants involved in quality of life to improve
patient care.
Identifying Available Data Sets
We need large-scale data sets of general populations
that include both genetic and quality-of-life variables.
To date, such data sets are scarce or at least untapped.
Exceptions are the Twin Registries of, for example,
Australia, The Netherlands, and Sweden, which
include both genetic and quality-of-life data. Open
access databases (e.g., via dbGAP Web portal) rarely
include quality-of-life data. We expect this to change
rapidly. Large-scale, longitudinal, population-based
studies focusing on different phenotypes, including
quality-of-life related variables, are increasingly col-
lecting biomarkers, and/or DNA for targeted or
genome-wide sequencing. Examples include household
panels, such as the British Household Panel Survey
and the German Socio-Economic Panel.
We also need large-scale data sets of disease popu-
lations. To date, many clinical trials include both
genetic markers and quality-of-life data, such as those
conducted by the North Central Cancer Treatment
Group and the European Organization for Research
and Treatment of Cancer. However, sample sizes are
relatively small and DNA analysis is usually restricted
to a limited number of genes that are primarily
involved in cancer. Ongoing, large-scale patient-based
studies collecting clinical and biological data may be
of interest as they may purport the addition of quality-
of-life data. For example, a Dutch cohort of congenital
heart disease patients and Swedish cohorts on breast
and prostate cancer patients will start collecting
quality-of-life data.
Since the availability of such data sets is key to fur-
thering this field, the Consortium aims to stimulate
international and interdisciplinary collaboration to
enable the combined collection of genetic and quality-
of-life data and the pooling of such data sets in
general and disease populations.
Delineating the Analytical Approach
The following three approaches will be conducted,
separately and/or in combination, wherever possible
and appropriate. First, advances in molecular and
genetic technology now enable the use of whole
genome scanning. Such GWA studies are conducted
without a specific hypothesis on the genes and path-
ways involved because thousands of single nucleotide
polymorphisms (SNPs) can be examined simultane-
ously. However, the costs involved and the need for
enormously large samples may render this approach
not very feasible.
Second, another type of association study is
hypothesis-driven focused on candidate genes exam-
ined in specific pathways. SNPs with frequency of at
least 5% are sufficiently prevalent to be candidates for
genetic association studies. Sequencing a selection of
the aforementioned candidate genes is a viable option
and can identify both common and rare variants.
Third, in addition to simple sequence variations,
we can analyze changes in copy number of a small
part of the genome, so called copy number variants
(CNVs). For CNV analysis one can analyze existing
GWA data, but many CNVs will be missed. However,
in case an association is found with a quality-of-life
dimension/phenotype one can perform a detailed
analysis of these regions. This can be either a direct
copy number analysis or a sequence-based approach.
Discussion
The field of patient-reported quality of life has never
focused on that which is innate to the person. Thus,
there is a compelling need to reveal the genetic vari-
ables that play a role in patient-reported quality of
life. Clearly, this path is complex, considering the
potential number of genes, the interaction between
these genes, the interaction between genes and envi-
ronmental (e.g., life style) factors, and the number of
quality-of-life variables that may be involved. To date,
genetic research has burgeoned thanks to technical
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advancements, such as high-throughput genotyping.
However, in pursuing the delineation of the relation-
ship between genes and quality of life, both genetic
and quality-of-life research is hindered by a mono-dis-
ciplinary approach. Few genetic researchers are
working with patient-reported quality-of-life end-
points, and similarly few quality-of-life researchers are
engaged in genetic research. It is of paramount impor-
tance to join forces among the disparate disciplines.
Therefore, we have established the international and
interdisciplinary GENEQOL Consortium to provide
the requisite foundation and research culture to stimu-
late the development of this field. We were able to
broach the language barriers of the disciplines
involved. Interestingly, we found more commonality
of the diverse experiences and were closer to outlining
the biological pathways and genetic variables involved
in the target quality-of-life outcomes and in setting a
research agenda than we had anticipated. We hereby
purport to adopt a sound scientific procedure integrat-
ing and building on the extant knowledge gained in
the relevant disciplines. This is particularly important
since genetic research is faced with many challenges,
such as weak gene–disease associations (Khoury et al.,
2007) and inconsistency of results (Ioannidis, 2007).
Finding the optimal path to uncover the relationships
between genetic variants and patient-reported quality-
of-life variables will be a challenge in itself.
One of the advantages of studying the genetic dis-
position of quality of life, which encompasses multiple
domains, is that it allows the investigation of overar-
ching questions that are not likely to be addressed by
consortia focusing on only one domain, e.g., depres-
sion or fatigue. The current knowledge regarding the
biological pathways, and genetic variables involved in
the five identified quality-of-life domains points to a
number of such intriguing questions.
First, to what extent are negative and positive
affect opposite ends of the same continuum? For
example, the dopamine system is involved in negative
as well as positive affect. The question arises whether
the genetic influences overlap entirely or only in part.
Genetic analyses are needed to disentangle the biologi-
cal and genetic substrates of negative and positive
affect, using data sets that include information on
both phenotypes.
Second, given the high degree of biological and
genetic overlap among these and other quality-of-life
components, the question arises what part of the bio-
logical substrate is shared and what is unique to each
component? For example, the genes that influence
well-being and depressive symptoms are to a large
degree the same genes that influence self-rated health
and personality. Furthermore, genes in the cytokine
pathway do not only control depression but also pain
and fatigue (Reyes-Gibby et al., 2007, 2008; Irwin et
al., 2007) and thus also self-rated health. Given the
biological and genetic overlap of quality-of-life
domains one may wonder whether we should expand
our focus even further to include the wider fitness of
the organism. For example, the combined use of a
variety of measures may be most informative, includ-
ing measures of: (1) brain functioning (EEG, MRI); (2)
mental health (depression, anxiety, happiness); (3) per-
sonality (extraversion, internalization, neuroticism);
(4) physiological functioning (HPA axis, immune
system, autonomic nervous system); and (5) cogni-
tive/neuropsychological functioning.
Third, genetic research requires very large sample
sizes, which may be achieved primarily by pooling dif-
ferent data sets. The question then arises whether
different operationalizations of the same construct
affect the findings. In other words, can we pool data
sets that include different quality-of-life measures?
Studies are needed that examine the extent to which
different measures assessing similar quality-of-life
domains are based on one or more underlying biologi-
cal substrates.
Fourth, the studies to date were conducted in both
healthy volunteers and ill patients. The question arises
to what extent the findings in healthy individuals are
applicable to somatically or psychiatrically ill patients,
and vice versa. For example, the extent to which nega-
tive affect behaves as a continuous trait where the
same biological and genetic mechanisms are at stake
in clinical depression as in nonpathological somber-
ness remains to be empirically tested. Another
example is pain. Studies are needed that increase our
insight into the relevant biological mechanisms under-
lying pain experience. Preclinical studies may be
performed where pain is experimentally induced in
healthy volunteers, who are opioid naïve, and do not
take other medication. The question about the extent
to which the findings of such studies are applicable to
patients needs to be examined in clinical studies in, for
example, cancer patients, who have comorbidities and
multiple medications to treat these conditions, includ-
ing long-term opioids. Clearly, the applicability of the
findings in other respondent groups needs to be con-
tinuously empirically examined.
The fifth but far from trivial question is how to
move forward practically. Analyses of biological path-
ways will be a challenge because of the type of tissue
required, which likely needs to be obtained from the
CNS. Therefore, a first practical approach of the con-
sortium will be the use of blood samples to establish
genetic background (e.g., genetic variants) and gene
expression profiles (e.g., cytokine levels) in relation to
patient-reported quality of life.
With the establishment of the GENEQOL
Consortium, it is our hope that the intriguing ques-
tions surrounding the genetic disposition of quality of
life will be set on the research agenda and be studied
widely. The GENEQOL Consortium aims to facilitate
such investigations by supporting communication
among members and with others outside the
Consortium, and thus enabling networking and access
to knowledge, skills, and ideas. The overall aim is to
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compile and pool existing and new data to carry out
genetic analyses. As a means of communication within
the Consortium and with others outside the
Consortium, a website was built — www.geneqol.org
— with open access and restricted access for
Consortium members only. We actively welcome new,
contributing members who are willing to identify rele-
vant studies, obtain access to existing data sets,
volunteer for tasks, or forward new and useful ideas
and suggestions. Such combined efforts are needed to
further research into the relatively novel question
about the genetic disposition of quality of life.
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